Antibody–drug conjugates (ADCs) reshaped cancer treatment by combining the precision of targeted antibodies with the potency of cytotoxic therapies, but as the field matures, the focus is shifting toward making ADCs not only more effective, but safer and more tolerable for patients. This session brings together leaders in oncology, R&D, bioconjugation chemistry, and translational medicine to examine how next-generation ADCs - through smarter linkers, novel payloads, improved selectivity, and more patient-friendly dosing strategies - are redefining targeted therapy. Panelists will discuss advances aimed at reducing off-target toxicity, improving durability of response, and leveraging biomarkers and combination approaches, asking whether the next wave of ADC innovation can fully realize the promise of precision medicine by delivering powerful cancer therapies with less burden on patients.